Feature Story

Kara McKinley named Packard Fellow for Science and Engineering

October 18, 2022

 

Kara McKinley, PhD, principal faculty at HSCI, has been named one of the 2022 class of Packard Fellows for Science and Engineering. McKinley and 19 other innovative early-career scientists and engineers will each receive $875,000 over five years to pursue their research.

The Packard Fellowships for Science and Engineering are designed to encourage innovative, blue-sky thinking by providing maximum flexibility and support to...

Read more about Kara McKinley named Packard Fellow for Science and Engineering

A new therapy for treating Type 1 diabetes

October 20, 2021

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes